Bioanalysis is the quantitative measurement of drugs, their breakdown products, or other compounds in biological fluids like blood, plasma, urine, and tissue. It’s the science that answers a deceptively simple question in drug development: after someone takes a medication, how much of it actually ends up in the body, and where does it go? Every drug that reaches the market has been through extensive bioanalytical testing, making it one of the foundational disciplines in pharmaceutical science.
What Bioanalysis Measures and Why
When a drug enters the body, it doesn’t stay in its original form for long. It gets absorbed, distributed to various tissues, broken down by the liver, and eventually eliminated. Bioanalysis tracks this entire journey by measuring drug concentrations in samples taken at specific time points. The resulting data tells researchers how quickly a drug is absorbed, how long it stays active, and whether it accumulates in places it shouldn’t.
This information feeds directly into dosing decisions. If bioanalytical data shows a drug clears from the bloodstream within four hours, that shapes whether the final product is dosed once or twice daily. If it shows the drug or its breakdown products linger in kidney tissue, that raises safety questions that need answers before the drug can move forward. Without reliable concentration measurements, there’s no way to design a safe, effective dosing regimen.
Biological Samples Used in Testing
The most common sample types are blood plasma and serum, both collected through standard blood draws. Plasma is the liquid portion of blood separated before clotting, while serum is separated after clotting. Urine is another frequently analyzed sample, especially for drugs eliminated through the kidneys. Tissue extracts, cerebrospinal fluid, saliva, and even tears can also be analyzed depending on the drug and the study’s goals.
A newer approach uses dried blood spots, where a few drops of blood from a simple finger prick are collected on a special card. The sample volume is far smaller than a traditional blood draw, making collection easier for patients and particularly useful in pediatric studies. Dried blood spots also don’t require temperature-controlled shipping. They can be mailed in lightweight packages at room temperature, cutting the logistical costs and infection risks associated with transporting liquid biological samples.
How Small Molecule Drugs Are Measured
Most traditional pharmaceutical drugs are small molecules: aspirin, statins, blood pressure medications. For these, the gold standard analytical technique is liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). This technology first separates the drug from everything else in the biological sample, then identifies and quantifies it based on its molecular weight and structure. It’s favored for its selectivity, sensitivity, and reliability across thousands of samples.
Before a sample reaches the instrument, the drug needs to be extracted from the complex biological mixture of proteins, fats, and salts that make up blood or plasma. Two primary extraction techniques dominate. Liquid-liquid extraction works by mixing the sample with a solvent that the drug preferentially dissolves into, pulling it away from the biological material. It’s simple and produces high recovery rates. Solid-phase extraction passes the sample through a specially designed cartridge that traps the drug while washing away everything else. It’s faster and more easily automated. Both methods are routinely used across the pharmaceutical industry, and some workflows combine elements of each.
How Biologic Drugs Are Measured
Biologics are a different category altogether. These are large, complex molecules like therapeutic antibodies, proteins, and gene therapies. They’re too large and structurally intricate for standard LC-MS/MS, so they require a different approach: ligand binding assays.
The most common type is the ELISA (enzyme-linked immunosorbent assay), which uses specially designed antibodies that recognize and bind to the therapeutic drug. Think of it like a lock-and-key system. The assay antibody locks onto a specific region of the drug molecule, and a chemical reaction produces a measurable signal proportional to how much drug is present. Electrochemiluminescence assays work on a similar principle but offer greater sensitivity.
One advantage of ligand binding assays is their ability to distinguish between “free” drug (the portion actively available to work in the body), “bound” drug (attached to proteins or its target), and total drug. This distinction matters because only free drug is pharmacologically active. Having all three measurements allows researchers to build more accurate models of how a biologic behaves over time.
Regulatory Standards for Accuracy
Bioanalytical methods can’t just work in a general sense. They have to be formally validated to strict regulatory standards before any data they produce can support a drug application. The FDA’s guidance on bioanalytical method validation spells out exactly how accurate and precise a method must be.
For chromatographic methods used on small molecules, measured values must fall within 15% of the true concentration. At the lowest measurable level, called the lower limit of quantitation, the tolerance widens slightly to 20%. The method must also produce consistent results when repeated: precision, measured as the scatter between replicate measurements, follows the same 15% and 20% thresholds. The lowest measurable concentration itself must produce a signal at least five times greater than the background noise and hit accuracy between 80% and 120% of the true value.
Ligand binding assays for biologics get wider tolerances because of the inherent variability in antibody-based measurements. Standard concentrations must fall within 20% of their target values, with 25% allowed at the upper and lower extremes. During actual study analysis, at least two-thirds of quality control samples must meet these accuracy thresholds for a batch of results to be accepted.
These aren’t optional recommendations. If a bioanalytical method fails to meet these criteria during validation, the data it generates won’t be accepted by regulatory agencies. Every number in a drug’s pharmacokinetic profile traces back to a validated method that meets these standards.
Where Bioanalysis Fits in Drug Development
Bioanalysis isn’t confined to a single phase of development. It runs through the entire process. In early discovery, it helps screen drug candidates by measuring how well they’re absorbed and how quickly they’re cleared. During preclinical studies in animals, bioanalytical data reveals whether a compound reaches toxic concentrations in specific organs. In clinical trials with human volunteers, it generates the pharmacokinetic profiles that regulators review when deciding whether a drug is safe and effective at its proposed dose.
Beyond drug development, bioanalytical techniques are used in anti-doping testing, forensic toxicology, clinical diagnostics, and therapeutic drug monitoring for patients on medications with narrow safety margins. The same core principles apply across all these fields: take a biological sample, extract the compound of interest, and measure it with enough accuracy to make meaningful decisions.